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Microarray analysis on pooled samples has previously identified ZDHHC9 (DHHC9) to be upregulated in colon adenocarcinoma
compared to normal colon mucosa. Analyses of 168 samples from proximal and distal adenocarcinomas using U133plus2.0
microarrays validated these findings, showing a significant two-fold (log 2) upregulation of DHHC9 transcript (Po106). The
upregulation was more striking in microsatellite stable (MSS), than in microsatellite instable (MSI), tumours. Genes known to interact
with DHHC9 as H-Ras or N-Ras did not show expression differences between MSS and MSI. Immunohistochemical analysis was
performed on 60 colon adenocarcinomas, previously analysed on microarrays, as well as on tissue microarrays with 40 stage I– IV
tumours and 46 tumours from different organ sites. DHHC9 protein was strongly expressed in MSS compared to MSI tumours,
readily detectable in premalignant lesions, compared to the rare expression seen in normal mucosa. DHHC9 was specific for tumours
of the gastrointestinal tract and localised to the Golgi apparatus, in vitro and in vivo. Overexpression of DHHC9 decreased the
proliferation of SW480 and CaCo2 MSS cell lines significantly. In conclusion, DHHC9 is a gastrointestinal-related protein highly
expressed in MSS colon tumours. The palmitoyl transferase activity, modifying N-Ras and H-Ras, suggests DHHC9 as a target for
anticancer drug design.
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Colon cancer is among the most frequent cancers in the Western
World with an overall 5 years survival around 50% (Lv et al, 2006).
Early diagnosis is a key for cancer survival, as early-stage tumours
have a better prognosis. Therefore, it is relevant to identify new
biomarkers for early lesions. We identified DHHC9 as an early
colon cancer biomarker both at the transcript and protein levels.
Two major molecular subgroups of colon cancer exist, micro-
satellite instable (MSI) and microsatellite stable (MSS) (Fearon and
Vogelstein, 1990; Lengauer et al, 1997), where MSI tumours
represent approximately 15% of the total incidence (Clark et al,
2004). Microsatellite instable tumours show mutations or epi-
genetic alterations in the mismatch repair genes that lead to
alterations in microsatellite DNA (short repeated sequences of
DNA). Increasing evidence suggests that MSI tumours are
associated with better prognosis (Clark et al, 2004) and that
patients with MSI may not benefit from fluorouracil-based
adjuvant chemotherapy (Ribic et al, 2003; Benatti et al, 2005).
A differential behaviour of single molecules in MSS and MSI
tumours may help understanding the molecular basis of these two
subgroups and their associated prognostic and therapeutic
implications. In the present investigation, we analysed these two
subgroups with regard to DHHC9 expression.
In our previous study, microarray expression profiling identi-
fied a subset of several hundred expressed sequence tags (ESTs)
differentially expressed in pools of distal sporadic colon cancer
(Dukes’ stages A, B, C and D) when compared to pools of normal
mucosa (Birkenkamp-Demtroder et al, 2002). One of these was
EST AA232508, identified as part of the ZDHHC9 gene and
strongly upregulated in all cancer stages (Birkenkamp-Demtroder
et al, 2002). Very recently, the protein encoded by the ZDHHC9
gene, DHHC9, has been characterised. DHHC9 is a 364 amino-acid
membrane-bound protein characterised by its Asp-His-His-Cys
(DHHC) sequence, within a cysteine-rich domain (Swarthout et al,
2005). DHHC9 forms a complex with a Golgi-associated protein of
16 kDa, GCP16. This DHHC9– GCP16 complex has been associated
with a protein fatty acyltransferase (PAT) activity, with in vitro
specificity for H-Ras and N-Ras (Swarthout et al, 2005).
Palmitoylation of Ras increases the affinity of farnesylated Ras
for membranes (Dudler and Gelb, 1996), where Ras can be stably
anchored (Berthiaume, 2002). Palmitoylation also facilitates Ras
transport (Choy et al, 1999; Apolloni et al, 2000), which
contributes to its biological function in signal-transduction
pathways.
In this study, we analysed the expression of DHHC9 mRNA in
168 colorectal adenocarcinomas sampled in Denmark, The Nether-
lands and Finland, using microarrays. We also studied the protein
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expression pattern in more than a hundred samples including
formalin-fixed paraffin-embedded (FFPE) sections and tissue
microarrays (TMAs) using a monospecific polyclonal antibody
raised against DHHC9. In vitro studies of COS7 cells over-
expressing DHHC9 and colocalisation studies on FFPE specimens
demonstrated a Golgi-restricted expression of DHHC9.
Overexpression of DHHC9 decreased the proliferation rate of
SW480, CaCo2 and DLD-1 with enabled wnt signalling, signifi-
cantly.
In conclusion, DHHC9 is strongly upregulated in adenocarci-
nomas of the gastrointestinal tract. The microsatellite status of
colon adenocarcinomas distinguishes two highly different mole-
cular subgroups of colon cancer regarding DHHC9 expression.
MATERIALS AND METHODS
Clinical specimens
We analysed 168 colorectal samples from patients in Denmark
(n¼ 108), The Netherlands (n¼ 56), and Finland (n¼ 14),
comprising 122 colon and 46 rectum cancers (Supplementary
Table 1). Ten normal mucosa biopsies from the resection edge
were collected from Danish patients. Informed consent was
obtained from patients, and the local scientific ethical committees
approved the study.
Tissue handling, nucleic acid isolation and microsatellite
analysis
The specimens were obtained fresh from surgery and immediately
snap-frozen in liquid nitrogen either in an SDS/guanidinium
thiocyanate solution or Tissue-Tek OCT compound and subse-
quently frozen (Denmark), or dry-frozen (Finland and The
Netherlands). Total RNA was isolated from the same piece of
tissue using Trizol (Invitrogen, Carlsbad, CA, USA). RNA was
checked on an Agilent Bioanalyzer and samples with a 28S to 18S
ribosomal RNA ratio lower than 1.0 were excluded. The micro-
satellite status of the tumours was analysed as described previously
(Suraweera et al, 2002; Kruhoffer et al, 2005). Tumours with low-
frequency MSI have similar clinical features as MSS tumours and
were considered as such in this study.
Gene expression analysis
Labelling of RNA, hybridisation and scanning were performed as
described (Dyrskjot et al, 2003). Biotin-labelled cRNA was
prepared from 10 mg of total RNA and hybridised to the Human
Genome U133plus2.0 GeneChip (Affymetrix, Santa Clara, CA,
USA) containing 455 000 probe sets. The readings from the
quantitative scanning were analysed by the Affymetrix Software
MAS5.0. The resulting cell-files for all 178 samples were imported
into ArrayAssist version 3.3 (Stratagene, La Jolla, CA, USA) and
data were normalised using GC-RMA (Bolstad et al, 2003; Irizarry
et al, 2003) as implemented in ArrayAssist.
Statistical analysis
Transcript values were expressed as median log 27s.d. A two-
tailed unequal variance t-test was used to determine the differences
of DHHC9 expression level in normal colon mucosa vs MSS and
MSI tumours, and between the MSS and MSI subgroups.
Differences with a P-value o0.05 were considered as statistically
significant.
Real-time RT– PCR and normalisation
Semiquantitative real-time RT–PCR was performed on 24 samples,
four MSI and MSS samples and their corresponding matching
normal mucosa as well as four additional MSI and MSS samples
with non-matching mucosa. cDNA was synthesised as described
(Andersen et al, 2004). RT–PCR analysis was performed in
triplicates using TaqMans probe assay ID Hs00211318_m1
(Applied Biosystems) as recommended by the manufacturers and
run on a 7500 Fast Real-Time PCR system (Applied Biosystems,
Foster City, CA, USA). Results were normalised against UBC,
as described previously (Birkenkamp-Demtroder et al, 2002;
Andersen et al, 2004).
RACE and plasmid construction
RACE was performed using a marathon ready colon adenoma
carcinoma cDNA library (Clontech, Mountain View, CA, USA)
with primers 50-UTR-GGGGGACATGTACACTCTTCTTCGC and
30-UTR-GCCACTGGAGGAAAGTGGAAGTCG.
Wild-type DHHC9 cDNA was PCR amplified from the cDNA
library mentioned above using primers sense 50-GGCAACA
TGTCTGTGATGGTGGTGAG and antisense 30-CTACTTCT
CAGCTTCAGCTGCCTCC. DHHC9 cDNA was cloned into pcDNA
3.1 bidirectional (Invitrogen) and the DNA sequence was verified.
Several normal and colon cancer patients’ cDNAs were synthesised
from total mRNA using Superscriptt cDNA synthesis kit
(Invitrogen).
Production of monospecific antibodies
Polyclonal rabbit anti-DHHC9 antibodies #EP384 were raised
against the peptide CKGSWTGKNRVQNPYS (amino acids 261–
274), conjugated to KLH. Antisera were affinity purified against the
peptide (Eurogentec, Seraing, Belgium).
Immunofluorescence microscopy
COS7 cells were cultured on RPMI 1640 medium supplemented
with 10% FCS and 1% penicillin–streptomycin at 371C and 5%
CO2 and transfected using lipofectamine (Invitrogen), following
the manufacturer’s instructions. Transfected COS7 cells were fixed
and permeabilised with cold methanol (201C) at room tempera-
ture. Four micrometres FFPE tissue samples were deparaffinised
and stained as described previously (Birkenkamp-Demtroder et al,
2005). Cells or FFPE specimens were stained with rabbit anti-
DHHC9 (1 : 100 cells, 1 : 250 FFPE) and mouse monoclonal anti-
58K (1 : 50 cells, 1 : 400 FFPE) (Abcam Ltd, Cambridge, UK).
Secondary antibodies were goat anti-rabbit highly cross-adsorbed
AlexasFluor 488 conjugated (Molecular probes; 1 : 2000 cells,
FFPE) in combination with goat anti-mouse AlexasFluor 546
conjugated (Molecular probes, Eugene, OR, USA; 1 : 800 cells,
1 : 1600 FFPE). Cells were stained with DAPI for nuclear
visualisation. Cells and FFPE tissues were mounted with Fluor-
escent Mounting Medium DakoCytomation, Glostrup, Denmark.
Visualisation was performed using a Zeiss Axiovert fluorescence
microscope with 1000 and  400 magnification or a Leica DMRS
confocal microscope with a 64HCX PlApo, 1.32 NA objective.
Images were merged using Image J and assembled with Adobe
Photoshop 9.0.
Cell proliferation assay
Cell proliferation assays were performed on HCT15, LS174 TR4,
HCT116, doxycycline-inducible (1 mg ml1) DLD-1 (van de Weter-
ing et al, 2002), CaCo2 and SW480 human colon cancer cells using
CyQUANTs NF (Invitrogen). Cell lines were grown as follows:
HCT15 in RPMI 1640 medium, SW480 in D-MEM medium,
HCT116 in McCoy medium, LS174 TR and DLD-1 in RPMI 1640
medium added HEPES. All cell lines were supplemented with 10%
FCS and 1% penicillin/streptomycin. A total of 400–10 000 cells
per well were transfected as described above. Dye binding solution
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(1 ) was added after 48 h post-transfection and fluorescence
intensities were measured using a Biotek FLEX800-TBIDE
fluorescence microplate reader at excitation 485/20 nm and
detection 528/20 nm. Assays were performed on six replicates per
cell line and per plasmid construction.
Immunohistochemistry
Samples consisted of 60 FFPE biopsies from the superficial non-
necrotic part of adenocarcinomas and/or normal mucosa biopsies
taken from the macroscopically normal resection margin pre-
viously analysed on microarrays (Birkenkamp-Demtroder et al,
2002; Kruhoffer et al, 2005). Biopsies from hyperplasic polyps,
adenomas and normal mucosa from the gastrointestinal tract were
taken through endoscopies.
The anti-DHHC9 antibody was applied to 4 mm FFPE sections
and stained, as described previously (Birkenkamp-Demtroder
et al, 2005).
Tissue microarrays were obtained from BioCat GmbH (Heidel-
berg, Germany). A ‘Colon Cancer Tissue Array COCA912-5-OL
(UICC staging)’ and a TMA with human tumours from multiple
organ sites and normal specimens from the same sites (T8235713-
5-BC) were stained for DHHC9 protein expression using a 1 : 250
dilution of the rabbit anti-DHHC9 antibody. Scoring of the TMAs
was independently performed by two experienced investigators
(FBS and KBD).
Cell extraction, SDS gels and Western blots
Transfected COS7 cells were harvested and lysed in lysis buffer
(50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1 mM DTT, 1% Triton X-100
and protease inhibitor ROCHE complete, EDTA free). Total
protein samples (10– 20mg) were run on 12% SDS gels (Invitrogen)
and transferred to nitrocellulose membranes. Membranes were
blocked with 3% w/v non-fat powder milk PBS. The primary
antibody was rabbit polyclonal anti-DHHC9 (1 : 100) and the
secondary antibody goat anti-rabbit HRP conjugated (1 : 5000)
(DakoCytomation). The immunoreactive bands were visualised
using ECL plus (Amersham biosciences, Piscataway, NJ, USA) and
a UVP ChemiDoc-It, Imaging system (UVP Inc., Upland, CA,
USA).
RESULTS
Microarray and RT– PCR analysis
Genome-wide expression profiling monitored the presence of
several transcripts corresponding to DHHC9 and proteins
described to interact with it, or sharing an evolutionary relation-
ship (Fukata et al, 2004). We found the DHHC9 transcript to be
overexpressed in colorectal cancer (CRC). We found a significant
two-fold log 2 increase (Po106) in transcript levels, when
adenocarcinoma tissue samples were compared to normal mucosa
samples (Figure 1A and Table 1). GCP16, GCP170 (Ohta et al,
2003), DHHC14 (Fukata et al, 2004), DHHC18 (Fukata et al, 2004)
and N-Ras, genes known to be related to DHHC9, showed a
moderate decrease or no change (Table 1 and Supplementary
Figure 1). H-Ras transcription was upregulated in CRC (1.3-fold
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Figure 1 Microarray analysis of 168 samples representing molecular subgroups of CRCs. Transcript expression level of (A) DHHC9 and (B) H-ras on the
U133plus2.0 Gene Chip. The black bars correspond to CRC samples, the grey bars to normal mucosa. Expression values are given as log 2 values and all data
are normalised. (C) MSS/MSI study. Median log 2 values and standard deviations of normal biopsies (median normal, n¼ 10), CRC patients (median cancer,
n¼ 168), MSI (CRC patients with MSI, n¼ 35), MSS (CRC patients with MSS, n¼ 118).
Table 1 Summary of microarray transcript profiling
Median log 2
MSS/MSI
N T Log 2 fold change P-value P-value
DHHC9 6.3 8.3 2.0 o106 o1013
GCP16 8.8 8.7 0.1 0.06 0.07
GCP170 8.6 8.2 0.4 o104 0.003
N-Ras 6.7 6.7 0 0.964 0.61
H-Ras 6.3 7.6 1.3 o104 0.008
DHHC14 5.0 4.5 0.5 0.01 0.61
DHHC18 5.2 5.3 0.1 0.18 0.002
MSI¼microsatellite instable; MSS¼microsatellite stable. Data are given as median
log 2, fold change between normal (N) and tumour (T) and P-value.
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change, Po104) (Figure 1B and Table 1), confirming previously
published data (Feng et al, 2001).
Out of 168 patient samples used in our microarray profiling
study, 118 were identified as MSS, and 35 were MSI. The remaining
15 samples were of unknown status.
Data analysis pointed out that DHHC9 transcript overexpression
differed significantly between MSS and MSI tumours (Po1013),
as depicted in Figure 1C. The MSS tumours (median log 2,
8.6) showed a 2.3-fold log 2 increase (Po107) of DHHC9
transcript when compared to normal mucosa, while MSI tumours
(median log 2, 7.3) showed a 1.0-fold log 2 increase (Po104).
In contrast to the DHHC9 transcript, the H-Ras transcript showed
a 0.3-fold log 2 increase between MSI and MSS samples
(Figure 1C).
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Figure 2 Immunohistochemical analysis of DHHC9 expression. (A) normal mucosa, (B) Dukes A adenocarcinoma adjacent to premalignant tissue, (C)
Dukes A adenocarcinoma ( 200), (D) Dukes D adenocarcinoma, (E) lymph node metastasis and (F) liver metastasis ( 400). DHHC9 protein expression
in MSS vs MSI colon adenocarcinomas. Microsatellite stable tumours (G–L), MSI-H tumours (M–R) ( 200).
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Real-time RT–PCR was consistent with those data as ZDHHC9
transcript expression was only slightly increased in MSI tumours
(median 1.1) but highly increased in MSS tumours (median 1.7)
when compared to matching normal mucosa samples (median
0.4), as shown in Supplementary Figure 2.
DHHC9 protein expression pattern in colon
adenocarcinomas, distant metastases and TMAs
Immunohistochemical analyses were performed on FFPE adeno-
carcinomas and their matching normal mucosa, all samples were
previously expression profiled (Birkenkamp-Demtroder et al,
2005; Kruhoffer et al, 2005). Matching normal mucosa was
either scored negative for DHHC9, or showed a very weak
DHHC9 expression in the cytoplasm of the luminal part of the
mucosa as shown in Figure 2A and in more detail in
Supplementary Figure 3.
DHHC9 protein was strongly upregulated in adenocarcinomas,
thereby accumulating supranuclear, probably in the Golgi
apparatus (Figure 2B and C)
To investigate whether DHHC9 was differentially expressed in
MSS compared to MSI tumours, immunohistochemical analyses
were performed on a subset of 34 colon adenocarcinomas with
known MSS/MSI status, previously expression profiled on
U133A2.0 arrays (Kruhoffer et al, 2005). The subset comprised
16 MSS and 18 MSI tumours and their matching normal mucosa.
Eighty-one per cent of the MSS tumours were positive for DHHC9,
showing a supranuclear accumulation of DHHC9 (Figure 2G–L),
while 77% of the MSI tumours were negative for DHHC9 (Figure
2M–R). Supplementary Figure 3 shows the staining results of
additional MSI (Supplementary Figure 3A–G) or MSS (Supple-
mentary Figure 3H –M) tumours, and their matching normal
mucosa. The scoring results are summarised in Table 2, and in
more detail in Supplementary Table 2.
Remarkably, upregulation of the DHHC9 protein was also
detected in early lesions such as benign hyperplasic polyps and
tubular and tubulo-villous adenomas (data not shown), as well as
at premalignant sites in the colon mucosa (Figure 2B and
Supplementary Figure 3N and O) These sites were either located
adjacent to, or in close proximity to, adenocarcinomas, for
example, detected at the transformation site (Supplementary
Figure 3Q). Moreover, accumulation of DHHC9 protein was also
identified in three lymph node metastases and 24 liver metastases
analysed. An example showing an adenocarcinoma and two
metastases from the same patient can be seen in Figure 2D–F.
To investigate whether differential expression of DHHC9 is stage
dependent, we analysed a colon cancer TMA comprising
adenocarcinomas of the UICC stages I–IV (Table 3). All 10
adenomas and 70 –80% of the four UICC stages of adenocarcino-
mas and liver metastases stained positive for DHHC9. Eighty per
cent of the normal mucosa samples were negative, only one
was moderately expressing the DHHC9 molecule, as shown in
Supplementary Figure 4.
In conclusion, DHHC9 is significantly upregulated in the
majority of MSS tumours at both the transcript and protein level.
Upregulation is detected at premalignant sites and in very early
lesions and is independent of stage and grade.
DHHC9 expression is confined to tumours of the
gastrointestinal tract
We analysed the DHHC9 protein expression pattern in 94 samples
comprising 46 cancers from different organ sites and 46 normal
tissues using a multiple cancer TMA. DHHC9 was either
moderately or not expressed in normal tissues of the body, as
shown in Supplementary Figure 5. Results are summarised in
Supplementary Table 3. Most common cancers such as, bladder,
prostate, breast, kidney, uterus, thyroid, lymph node, tongue or
brain were completely negative for DHHC9 expression (Supple-
mentary Figure 5). In contrast, all gastrointestinal adenocarcino-
mas from the colon rectum, small intestine and stomach showed a
very strong positive Golgi-like staining for DHHC9 (Supplemen-
tary Figure 5B5, F7, F11 and G7). Moreover, analyses of additional
10 normal mucosa specimens derived from the gastrointestinal
Table 2 Immunohistochemical analysis of DHHC9 protein expression applying a 1 : 250 dilution of anti-DHCC9 antibody on 34 CRC tissue samples
Negative Weak Total Moderate Strong Very strong Total
MSS 3 0 3 3 5 5 13
MSI 8 6 14 1 1 2 4
Negative or weak expression Moderate to strong expression
MSS 3/16 18.75% 13/16 81.25%
MSI 14/18 77.78% 4/18 22.22%
CRC¼ colorectal cancer; MSI¼microsatellite instable; MSS¼microsatellite stable. The intensity is classified as negative (comprising negative or weak) and positive (comprising
moderate, strong or very strong).
Table 3 Immunohistochemical analysis of DHHC9 protein expression applying a 1 : 250 dilution of anti-DHCC9 antibody to a colon cancer TMA
Normal mucosa Adenoma ADC I ADC II ADC III ADC IV Liver metastases
Total cases 10 10 10 10 10 10 11
Average age (years) 69 64 69 75 72 62 64
Male 6 5 5 2 6 4 7
Female 4 5 5 8 4 6 4
Staining
Negative 8 0 2 2 2 3 3
Positive 2 10 8 8 8 7 8
Strong 1 3 5 1 3 2 4
Moderate 1 7 3 7 5 5 4
TMA¼ tissue microarray. The intensity of the positive cases is further classified as moderate or strong.
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tract of healthy people (oesophagus, stomach, small intestine,
appendix, colon and rectum) were also negative for DHHC9
expression (data not shown).
Subcellular localisation of DHHC9 in colon
adenocarcinomas and transient overexpression of wild-
type DHHC9
Colocalisation studies using immunofluorescence microscopy were
applied to FFPE tissue samples of adenocarcinomas with MSS
status. DHHC9 colocalised with the Golgi marker 58K in the Golgi
apparatus of the tumour cells, as shown in Figure 3F–K.
The coding cDNA derived from Affymetrix probe set
222451_s_at (DHHC9) was amplified from a commercial colon
adenocarcinoma cDNA library or normal and colon cancer total
cDNAs. The sequences showed no mutations (data not shown). A
50- and 30-UTR RACE amplified DHHC9 transcript variant 1
(NM_016032), proving the expression of a full-length transcript in
CRC tissue.
Wild-type DHHC9 transiently overexpressed in COS7 cells
colocalised with the Golgi marker 58K to the Golgi apparatus
(Figure 3A and D). This coincides with recent findings of Golgi-
localised DHHC9 in the embryonic kidney cell line HEK293
(Swarthout et al, 2005) and the localisation in colon adenocarci-
nomas described above.
The specificity of the rabbit anti-DHHC9 antibody was
confirmed by Western blot analysis, identifying a 36 kDa band of
recombinant wild-type DHHC9 (Figure 3E).
Interestingly, the apparent molecular weight was 5 kDa lower
than that of the calculated molecular weight of 40.9 kDa. This
suggested that a cleavage of approximately 43–50 amino acids may
have taken place affecting the very basic N-terminus of the protein,
close to the predicted anchor signal (Lys35-Glu56). No bands were
detected in the mock protein cell extract from COS7 cells
transfected with an empty vector. There were no signs of cell
morphological changes upon DHHC9 transfection.
DHHC9 expression impacts proliferation of colon cancer
cell lines
Six colon cancer cell lines with MSS or MSI status were transiently
transfected with DHHC9 or a mock empty vector. Proliferation was
found to be decreased in SW480 and CaCo2 cell lines (MSS), while
HCT15, LS174 TR4 and HCT116 (MSI) were not affected, as shown
in Figure 4. All cell lines have an activated wnt-signalling pathway.
To investigate the effect of DHHC9 on cell proliferation in a
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Figure 3 Immunostaining and Western blotting of transiently transfected COS7 cells and immunofluorescence applied to an MSS adenocarcinoma. (A–
C) Confocal microscope, (D) Zeiss Microscope:  100. (A) DHHC9, (B) endogenous 58K protein, (C) merged DHHC9 and 58K protein, (D) DHHC9
Golgi localisation detail. DAPI-stained nuclei are blue. (E) Western blotting of extracts from DHHC9-transfected COS7 cells (MW, molecular weight
marker; 1, cells transfected with an empty vector; 2, cells transfected with wild-type DHHC9). (F–K) IF, (F) DHHC9, (G) 58K protein, (H) DAPI, (I) merge
(F) and (G); (J) merge (F), (G) and (H); (K) DAB staining of the same tumour.
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cellular model, we used modified DLD-1 cells where the beta-
catenin/TCF4 activity can be disrupted by overexpression of
dominant-negative TCF induced by doxycycline (van de Wetering
et al, 2002). DHHC9 overexpression did not impact proliferation of
DLD-1 cells with active wnt signalling. Remarkably, in addition to
the previously described effects in SW480 and CaCo2, DHHC9
decreased the proliferation in cells with enabled wnt signalling
compared to mock-treated cells.
DISCUSSION
Microarray analysis on 178 samples showed a significant
upregulation of the DHHC9 transcript in individual colorectal
tumour samples, when compared to normal mucosa. The
upregulation of the DHHC9 transcript as well as the DHHC9
protein was mainly seen in MSS tumours.
The only published data on DHHC9 showed abundant transcript
in the kidney, skeletal muscle, brain, lung and liver and moderate
expression in the thymus, spleen and peripheral blood leucocytes
based on a Northern blotting (Swarthout et al, 2005). In contrast,
SAGE anatomic viewer at NCBI, based on small 10 bp tags, showed
a very low expression of the DHHC9 transcript in almost all the
tissues tested (http://cgap.nci.nih.gov/SAGE). Our TMA-based data
showed that, apparently, only tumours of the gastrointestinal tract
were able to express the protein stably, and most of the other
tissues seemed to be consistent with the transcriptional SAGE
anatomic viewer profile.
Sporadic CRCs develop as a result of defects in pathways
involving either chromosomal instability (Fearon and Vogelstein,
1990) or microsatellite instability (Lengauer et al, 1997).
Although the DHHC9 transcript was identified to be slightly
upregulated in MSI tumours compared to normal mucosa, our
results showed that DHHC9 transcript levels were significantly
higher in MSS compared to MSI tumours.
DHHC9 has no repeats in the coding or promoter 50-UTR
regions. Sequencing of seven samples did not detect mutations in
any of the amplified DHHC9 cDNAs from several patients (data
not shown), leading to the conclusion that the coding sequence
was not affected by mismatch repair failures.
It is well known that MSS tumours are genomic instable
compared to MSS tumours.
Recently, genome-wide differences between MSS and MSI
colorectal tumours have identified the loss of Xq in 31% of the
MSS cases studied (Camps et al, 2006). We therefore investigated
the ZDHHC9 Xq26.1 locus. Our own analyses of 15 laser
microdissected colon adenocarinomas using Affymetrix Mapping
10K SNP arrays (Andersen et al, 2007) did not show loss or gain of
chromosomal material at Xq26.1. There was no significant
difference between male and female patients (P¼ 0.15). We
conclude that the cause of DHHC9 upregulation and the difference
in DHHC9 transcript level between MSS and MSI specimens is not
directly related to a chromosomal imbalance at the Xq26.1 locus.
We have previously reported a differential gene expression in
proximal compared to distal CRC tumours (Birkenkamp-Demtroder
et al, 2005). In the present study, there was no significant expression
difference between the proximal and distal colon with regard to the
DHHC9 transcript. However, there was a tendency for MSI tumour
samples to be originated in the right side, while MSS tumours are
mostly left sided, as previously reported (Sugai et al, 2006).
DHHC9 transcripts were slightly upregulated in MSI tumours
compared to normal mucosa. However, the protein itself was
weakly expressed or absent in 77% of the MSI tumour samples. We
may therefore consider a very rapid turnover of the protein, so it is
not detectable, or there may be a tight regulation of the transcript,
and consequently no translation will occur in MSI tumours.
Interestingly, proliferation of MSS cell lines SW480 and CaCo2,
48 h post-DHHC9 transfection, showed a slight but significant
decrease of the proliferation rate. In contrast, DHHC9 over-
expression had no impact on the proliferation of MSI cell lines
HCT116, HCT15, LS174 TR4 and DLD-1. All these cell lines have a
constitutive active wnt-signalling pathway.
As expected, abrogation of wnt signalling significantly reduced
proliferation in DLD-1 cells (van de Wetering et al, 2002).
However, it cannot be excluded that part of the proliferation
decreasing effect can be attributed to doxycycline treatment alone,
as previously reported (Onoda et al, 2006). Surprisingly, the
combination of wnt abrogation with a simultaneous DHHC9
overexpression yielded an even more dramatic reduction in
proliferation than the wnt abrogation alone. These results may
suggest a potential involvement for DHHC9 in the control of
cellular proliferation. As a hypothesis, DHHC9 upregulation after a
cellular damage may contribute to an arrest in the cell cycle. This
arresting effect seemed to be associated to the MSS status, as only
SW480 and CaCo2 transfected cells showed a decreased prolifera-
tion rate. Later on, other factors may probably counteract the
antitumourigenic effect of DHHC9. Our data suggested that the
potential effect of DHHC9 overexpression was independent of an
active wnt-signalling pathway and had a synergistic effect upon
abrogated wnt-signalling conditions. In addition, the highly
tumourigenic, poorly differentiated SW480 cell line and the well-
differentiated CaCo2 showed a comparable decrease of the
proliferation rate upon DHHC9 overexpression.
The function and location of the protein may suggest the
implications of the DHHC9 expression in tumours. We localised
the DHHC9 protein in the Golgi apparatus in both colon
adenocarcinomas and transfected COS7 cells.
The DHHC9 protein has recently been described as a protein
acyl transferase PAT specific for N-Ras and H-Ras (Swarthout
et al, 2005). In vitro, DHHC9 and GCP16 are needed to carry out
the palmitoyl transferase activity. Our transcript profiling identi-
fied DHHC9 transcript levels to be highly upregulated in MSS
tumours compared to normal mucosa while GCP16 and N-Ras
showed no differential expression in CRC. It is tempting to suggest
that high DHHC9 levels of expression may have an impact on
N-Ras or H-Ras affecting its trafficking, modifying their acylation
rate cycle regulation (Rocks et al, 2005) or affecting clusters of GTP
bound, palmitoylated H-Ras and N-Ras, the so-called rasosomes
(Rotblat et al, 2006).
In this context, proteins that are responsible for post-transla-
tional modifications are particularly suitable as potential antic-
ancer drug targets (Leonard, 1997; Waddick and Uckun, 1998).
Palmitoylation of N-Ras and H-Ras, a post-translational modifica-
tion that takes place right after farnesylation, could become a new
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Figure 4 Proliferation assay. Several different cell lines with MSS
(SW480, CaCo2) or MSI (HCT15, HCT116, LS174 TR4, DLD-1) were
transfected with DHHC9 or a mock empty vector. Forty-eight hours post-
transfection cells were added to 1 dye binding solution, and fluorescence
was measured. Only MSS cell lines SW480 and CaCo2 showed a
significantly decreased proliferation rate. Interestingly, also DLD-1 cells, with
the wnt pathway switched off, showed a similar decreased proliferation
rate.
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target. Unfortunately, although PAT activity is well known, the
enzymes responsible for it are still elusive. However, the fact that
DHHC9 has been postulated to be a PAT specific for both N-Ras
and H-Ras, together with our results showing specific over-
expression of the protein in gastrointestinal cancers already at the
early stages of the disease, could be a first opening.
The role of DHHC proteins in cancer is just emerging. In this
study, we bring forth a new perspective on ZDHHC9. We showed
that ZDHHC9 is significantly increased in CRC at the transcript
and protein levels reflecting a significant difference between MSS
and MSI tumours. In addition, the postulated specific PAT
function of DHHC9, modifying N-Ras and H-Ras, suggests a very
interesting potential as anticancer drug target.
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